Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
The introduction of 'Definisse Core Filler' is a testament to the company's premium scientific-based innovation
Lupin has been exclusively marketing these brands in the Indian market since July 2021
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
The groundbreaking SPF technology is specifically designed and formulated to prevent sunburn or sun damage while allowing the passage of sufficient UVB light that our bodies use to naturally produce vitamin D
It provides Covid-19 detection and Omicron surveillance in less than two hours
Submission based on results from pivotal phase III trial showing all primary endpoints met
International Business is expected to register double-digit growth in constant currency terms
Subscribe To Our Newsletter & Stay Updated